Article · 30 Apr 2025
OtherPublished 22 Jul 2016
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Factor XIII (FXIII) is composed of two catalytic A subunits and two carrier B subunits. Following activation by thrombin FXIII becomes plasma transglutaminase, which crosslinks the γ-glutamyl-ɛ-lysine residues of fibrin chains stabilizing fibrin clot. Congenital deficiency of factor XIII results in a severe life-long hemorrhagic disorder, abnormal wound healing in about 30% of patients and recurrent abortions. Most of the FXIII deficiency patients have mutations in the F13A gene. Only few mutations in F13B gene have been published. Plasma-derived concentrate of factor XIII used to be the treatment of choice. Recently, recombinant FXIII concentrate has been developed and tested in multinational clinical studies. This new product appears to be safe and appropriate for life-long prophylactic treatment of patients with FXIII A deficiency.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Investigation.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Aida Inbal”